News Releases

2009

December

2 DEC 2009

Corporate

Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration

November

25 NOV 2009

Pharmaceuticals

U.S. Food and Drug Administration Approves ABILIFY^® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

September

8 SEP 2009

Nutraceuticals

New addition to CalorieMate^® line of balanced nutrition blocks CalorieMate^® Block, Maple Flavor First new flavor in two years debuts September 29

August

26 AUG 2009

Nutraceuticals

New SOYJOY flavored with blueberries and white chocolate chips SOYJOY Blueberry Debuts September 29, 2009

17 AUG 2009

Corporate

Otsuka Pharmaceutical Supports 8^th Annual Wheelchair Basketball Camp in Ibaraki held from August 14-16, 2009

14 AUG 2009

Corporate

20^th Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki'09 on August 13, 2009

4 AUG 2009

Pharmaceuticals

The European Commission Approves SAMSCA^™ (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .

July

13 JUL 2009

Nutraceuticals

Pocari Sweat in 900ml PET Eco-bottles New lightweight eco-bottles achieve 30% reduction in packaging weight

June

19 JUN 2009

Corporate

Otsuka Pharmaceutical Co., Ltd -- Fiscal Year through March 2009 Non-consolidated Results of Otsuka Pharmaceutical Co., Ltd. (PDF: 298.2 KB)

19 JUN 2009

Corporate

Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF: 157.8 KB)

May

21 MAY 2009

Pharmaceuticals

FDA Approves SAMSCA^™ (tolvaptan), The First and Only Oral Vasopressin Antagonist to Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia

April

6 APR 2009

Corporate

Otsuka Pharmaceutical Special Sponsorship Pocari Sweat U-12 Soccer League

6 APR 2009

Corporate

Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration

March

31 MAR 2009

Corporate

20th Anniversary Edition Published March 31 OTSUKA Health Comic Library Sequel Vol. 2 "Explore! All About Our Bodies" Educational comic series donated to elementary schools nationwide

27 MAR 2009

Nutraceuticals

Make-up removers formulated with moisturizing ingredient AMP expand the InnerSignal line of skin care products gentle, thorough removal of sebum and makeup

25 MAR 2009

Pharmaceuticals

Antipsychotic agent ABILIFY_® Oral Solution 0.1% to be Launched on April 10, 2009 in Japan

12 MAR 2009

Corporate

Otsuka Pharmaceutical Supports Anti-Doping Efforts through Participation in “ Pharmacist” Project

February

26 FEB 2009

Nutraceuticals

Third product in fruit soy bar SOYJOY 'Plus' series SOYJOY Banana Calcium Plus Debuts April 1, 2009

25 FEB 2009

Nutraceuticals

Produced by Amino-Value“Virtual Tokyo Marathon 2009”Select your favorite avatar and challenge the 42.195km run

January

30 JAN 2009

Corporate

Otsuka Pharmaceutical Established Otsuka Shanghai Research Institute in China for Innovative Drug Discovery Research

29 JAN 2009

Nutraceuticals

2009

Galenea and Otsuka Announce Second Extension to Schizophrenia Research Collaboration

U.S. Food and Drug Administration Approves ABILIFY® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

New addition to CalorieMate® line of balanced nutrition blocks CalorieMate® Block, Maple Flavor First new flavor in two years debuts September 29

New SOYJOY flavored with blueberries and white chocolate chips SOYJOY Blueberry Debuts September 29, 2009

Otsuka Pharmaceutical Supports 8th Annual Wheelchair Basketball Camp in Ibaraki held from August 14-16, 2009

20th Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki'09 on August 13, 2009

The European Commission Approves SAMSCA™ (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .

Pocari Sweat in 900ml PET Eco-bottles New lightweight eco-bottles achieve 30% reduction in packaging weight

Otsuka Pharmaceutical Co., Ltd -- Fiscal Year through March 2009 Non-consolidated Results of Otsuka Pharmaceutical Co., Ltd. (PDF: 298.2 KB)

Otsuka Pharmaceutical Co., Ltd. Appoints the Board Members and Statutory Auditors (PDF: 157.8 KB)

FDA Approves SAMSCA™ (tolvaptan), The First and Only Oral Vasopressin Antagonist to Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia

Otsuka Pharmaceutical Special Sponsorship Pocari Sweat U-12 Soccer League

Otsuka and Bristol-Myers Squibb Extend U.S. Agreement for ABILIFY and Establish a Global Oncology Collaboration

20th Anniversary Edition Published March 31 OTSUKA Health Comic Library Sequel Vol. 2 "Explore! All About Our Bodies" Educational comic series donated to elementary schools nationwide

Make-up removers formulated with moisturizing ingredient AMP expand the InnerSignal line of skin care products gentle, thorough removal of sebum and makeup

Antipsychotic agent ABILIFY® Oral Solution 0.1% to be Launched on April 10, 2009 in Japan

Otsuka Pharmaceutical Supports Anti-Doping Efforts through Participation in “ Pharmacist” Project

Third product in fruit soy bar SOYJOY 'Plus' series SOYJOY Banana Calcium Plus Debuts April 1, 2009

Produced by Amino-Value“Virtual Tokyo Marathon 2009”Select your favorite avatar and challenge the 42.195km run

Otsuka Pharmaceutical Established Otsuka Shanghai Research Institute in China for Innovative Drug Discovery Research

UL・OS Line of Men's Skincare Launches Sunscreen Formulated with Moisturizing Ingredient AMP Initial launch in Kyushu and Okinawa, February 9

U.S. Food and Drug Administration Approves ABILIFY^® (aripiprazole) for the Treatment of Irritability Associated with Autistic Disorder in Pediatric Patients (Ages 6 to 17 Years)

New addition to CalorieMate^® line of balanced nutrition blocks CalorieMate^® Block, Maple Flavor First new flavor in two years debuts September 29

Otsuka Pharmaceutical Supports 8^th Annual Wheelchair Basketball Camp in Ibaraki held from August 14-16, 2009

20^th Annual Outdoor Concert Held at Otsuka Pharmaceutical Tokushima Wajiki Factory Exciting Summer in Wajiki'09 on August 13, 2009

The European Commission Approves SAMSCA^™ (tolvaptan), Europe's First and Only Oral Vasopressin Antagonist for Hyponatraemia Secondary to Syndrome of Inappropriate Antidiuretic Hormone Secretion (SIADH) .

FDA Approves SAMSCA^™ (tolvaptan), The First and Only Oral Vasopressin Antagonist to Treat Patients with Clinically Significant Hypervolemic and Euvolemic Hyponatremia

Antipsychotic agent ABILIFY_® Oral Solution 0.1% to be Launched on April 10, 2009 in Japan